Clinical Trials Logo

Advanced Malignant Neoplasm clinical trials

View clinical trials related to Advanced Malignant Neoplasm.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03051035 Terminated - Clinical trials for Advanced Malignant Neoplasm

First-in-Human Study of KO-947 in Non-Hematological Malignancies

Start date: April 6, 2017
Phase: Phase 1
Study type: Interventional

This phase 1 first-in-human (FIH) dose escalation study will determine the maximum tolerated dose (MTD) of KO-947 in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, non-hematological malignancies. If an MTD cannot be identified, a recommended phase 2 dose (RP2D) will be determined. In addition, two tumor specific extension cohorts may be conducted to further characterize the safety and tolerability of KO-947 and provide preliminary evidence of anti-tumor activity.

NCT ID: NCT03049397 Terminated - Clinical trials for Advanced Malignant Neoplasm

Enhancing Connections Program in Improving Family Adjustment in Patients With Incurable Cancer

Start date: April 5, 2017
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well the Enhancing Connections program improves family adjustment in patients with incurable cancer. Participating in an educational program with a co-parent to learn about ways to talk to a child about cancer may help parents and co-parents support their child with the parent's cancer and may help families communicate and function better.

NCT ID: NCT02940223 Terminated - Fatigue Clinical Trials

Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer

Start date: March 16, 2017
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well ethyl icosapentate and physical activity work in treating fatigue in patients with cancer that has spread from where it started to other places in the body. Ethyl icosapentate and physical activity may provide more robust and clinically effective improvement of cancer related fatigue, which may facilitate patients continuing cancer therapy since it would be tolerated and effective in controlling disease.